184 related articles for article (PubMed ID: 27344186)
1. TMPRSS4 as an emerging potential poor prognostic factor for solid tumors: A systematic review and meta-analysis.
Zeng P; Zhang P; Zhou LN; Tang M; Shen YX; Jin J; Zhu YQ; Chen MB
Oncotarget; 2016 Nov; 7(46):76327-76336. PubMed ID: 27344186
[TBL] [Abstract][Full Text] [Related]
2. Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis.
Zeng P; Chen MB; Zhou LN; Tang M; Liu CY; Lu PH
Sci Rep; 2016 Sep; 6():33658. PubMed ID: 27645103
[TBL] [Abstract][Full Text] [Related]
3. Tetraspanin CD151 as an emerging potential poor prognostic factor across solid tumors: a systematic review and meta-analysis.
Zeng P; Wang YH; Si M; Gu JH; Li P; Lu PH; Chen MB
Oncotarget; 2017 Jan; 8(3):5592-5602. PubMed ID: 27888619
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of CD146 in solid tumor: A Systematic Review and Meta-analysis.
Zeng P; Li H; Lu PH; Zhou LN; Tang M; Liu CY; Chen MB
Sci Rep; 2017 Jun; 7(1):4223. PubMed ID: 28652617
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of CIP2A expression in solid tumors: A meta-analysis.
Tang M; Shen JF; Li P; Zhou LN; Zeng P; Cui XX; Chen MB; Tian Y
PLoS One; 2018; 13(7):e0199675. PubMed ID: 30044786
[TBL] [Abstract][Full Text] [Related]
6. High expression level of TMPRSS4 predicts adverse outcomes of colorectal cancer patients.
Huang A; Zhou H; Zhao H; Quan Y; Feng B; Zheng M
Med Oncol; 2013 Dec; 30(4):712. PubMed ID: 24072509
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic alterations leading to TMPRSS4 promoter hypomethylation and protein overexpression predict poor prognosis in squamous lung cancer patients.
Villalba M; Diaz-Lagares A; Redrado M; de Aberasturi AL; Segura V; Bodegas ME; Pajares MJ; Pio R; Freire J; Gomez-Roman J; Montuenga LM; Esteller M; Sandoval J; Calvo A
Oncotarget; 2016 Apr; 7(16):22752-69. PubMed ID: 26989022
[TBL] [Abstract][Full Text] [Related]
8. The upregulation of TMPRSS4, partly ascribed to the downregulation of miR‑125a‑5p, promotes the growth of human lung adenocarcinoma via the NF‑κB signaling pathway.
Fan X; Liang Y; Liu Y; Bai Y; Yang C; Xu S
Int J Oncol; 2018 Jul; 53(1):148-158. PubMed ID: 29750426
[TBL] [Abstract][Full Text] [Related]
9. TMPRSS4 Expression as a Marker of Recurrence in Patients with Lung Cancer.
Chikaishi Y; Uramoto H; Koyanagi Y; Yamada S; Yano S; Tanaka F
Anticancer Res; 2016 Jan; 36(1):121-7. PubMed ID: 26722035
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of TMPRSS4 expression in patients with breast cancer.
Liang B; Wu M; Bu Y; Zhao A; Xie F
Med Oncol; 2013 Jun; 30(2):497. PubMed ID: 23420063
[TBL] [Abstract][Full Text] [Related]
11. TMPRSS4 facilitates epithelial-mesenchymal transition of hepatocellular carcinoma and is a predictive marker for poor prognosis of patients after curative resection.
Wang CH; Guo ZY; Chen ZT; Zhi XT; Li DK; Dong ZR; Chen ZQ; Hu SY; Li T
Sci Rep; 2015 Jul; 5():12366. PubMed ID: 26190376
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of TMPRSS4 in prostate cancer.
Shi G; Yang X; Dai B; Zhang H; Shen Y; Zhu Y; Zhu Y; Xiao W; Ma C; Wen L; Qin X; Cao D; Ye D
Int J Clin Exp Pathol; 2014; 7(11):8053-8. PubMed ID: 25550850
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of FOXM1 in solid tumors: a systematic review and meta-analysis.
Li L; Wu D; Yu Q; Li L; Wu P
Oncotarget; 2017 May; 8(19):32298-32308. PubMed ID: 28427178
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of TMPRSS4 in gastric cancer.
Sheng H; Shen W; Zeng J; Xi L; Deng L
Neoplasma; 2014; 61(2):213-7. PubMed ID: 24299317
[TBL] [Abstract][Full Text] [Related]
15. TIM-3 is a potential prognostic marker for patients with solid tumors: A systematic review and meta-analysis.
Zhang Y; Cai P; Liang T; Wang L; Hu L
Oncotarget; 2017 May; 8(19):31705-31713. PubMed ID: 28423646
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of TMPRSS4 in non-small cell lung cancer is associated with poor prognosis in patients with squamous histology.
Larzabal L; Nguewa PA; Pio R; Blanco D; Sanchez B; Rodríguez MJ; Pajares MJ; Catena R; Montuenga LM; Calvo A
Br J Cancer; 2011 Nov; 105(10):1608-14. PubMed ID: 22067904
[TBL] [Abstract][Full Text] [Related]
17. Utility of TMPRSS4 as a Prognostic Biomarker and Potential Therapeutic Target in Patients with Gastric Cancer.
Tazawa H; Suzuki T; Saito A; Ishikawa A; Komo T; Sada H; Shimada N; Hadano N; Onoe T; Sudo T; Shimizu Y; Kuraoka K; Tashiro H
J Gastrointest Surg; 2022 Feb; 26(2):305-313. PubMed ID: 34379296
[TBL] [Abstract][Full Text] [Related]
18. PBK/TOPK overexpression and survival in solid tumors: A PRISMA-compliant meta-analysis.
Xu M; Xu S
Medicine (Baltimore); 2019 Mar; 98(10):e14766. PubMed ID: 30855480
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of IDO expression in solid tumors: a systematic review and meta-analysis.
Wang S; Wu J; Shen H; Wang J
BMC Cancer; 2020 May; 20(1):471. PubMed ID: 32456621
[TBL] [Abstract][Full Text] [Related]
20. TMPRSS4 is a novel biomarker and correlated with immune infiltration in thyroid carcinoma.
Xu X; Sun T; Jing J
BMC Endocr Disord; 2022 Nov; 22(1):280. PubMed ID: 36380313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
